Logo image of ADMA

ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

USA - NASDAQ:ADMA - US0008991046 - Common Stock

15.845 USD
-0.26 (-1.64%)
Last: 9/15/2025, 10:24:00 AM
Fundamental Rating

6

ADMA gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 540 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make ADMA suitable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
In the past 5 years ADMA reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

With an excellent Return On Assets value of 37.42%, ADMA belongs to the best of the industry, outperforming 98.89% of the companies in the same industry.
ADMA has a better Return On Equity (52.45%) than 98.89% of its industry peers.
ADMA has a Return On Invested Capital of 25.43%. This is amongst the best in the industry. ADMA outperforms 98.33% of its industry peers.
Industry RankSector Rank
ROA 37.42%
ROE 52.45%
ROIC 25.43%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin of ADMA (44.06%) is better than 98.52% of its industry peers.
Looking at the Operating Margin, with a value of 32.82%, ADMA belongs to the top of the industry, outperforming 97.41% of the companies in the same industry.
ADMA has a better Gross Margin (53.00%) than 75.74% of its industry peers.
ADMA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 32.82%
PM (TTM) 44.06%
GM 53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
Compared to 1 year ago, ADMA has more shares outstanding
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
ADMA has a better debt/assets ratio than last year.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ADMA has an Altman-Z score of 16.26. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 16.26, ADMA belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
ADMA has a debt to FCF ratio of 1.12. This is a very positive value and a sign of high solvency as it would only need 1.12 years to pay back of all of its debts.
ADMA has a better Debt to FCF ratio (1.12) than 94.44% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that ADMA is not too dependend on debt financing.
ADMA's Debt to Equity ratio of 0.18 is on the low side compared to the rest of the industry. ADMA is outperformed by 68.33% of its industry peers.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 1.12
Altman-Z 16.26
ROIC/WACC2.63
WACC9.67%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ADMA has a Current Ratio of 5.33. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.33, ADMA perfoms like the industry average, outperforming 57.96% of the companies in the same industry.
ADMA has a Quick Ratio of 2.78. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.78, ADMA is not doing good in the industry: 64.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 5.33
Quick Ratio 2.78
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

8

3. Growth

3.1 Past

ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 285.71%, which is quite impressive.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 43.58%.
The Revenue has been growing by 70.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)43.58%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%13.8%

3.2 Future

ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.01% yearly.
Based on estimates for the next years, ADMA will show a very strong growth in Revenue. The Revenue will grow by 22.46% on average per year.
EPS Next Y16.79%
EPS Next 2Y35.87%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.46%
Revenue Next 5Y22.46%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 29.34, ADMA can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 92.22% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of ADMA to the average of the S&P500 Index (27.30), we can say ADMA is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 17.16, the valuation of ADMA can be described as rather expensive.
ADMA's Price/Forward Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 93.52% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ADMA to the average of the S&P500 Index (22.73), we can say ADMA is valued slightly cheaper.
Industry RankSector Rank
PE 29.34
Fwd PE 17.16
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.15% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaper than 92.78% of the companies in the same industry.
Industry RankSector Rank
P/FCF 57.63
EV/EBITDA 23.4
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)1.75
PEG (5Y)N/A
EPS Next 2Y35.87%
EPS Next 3Y35.8%

More info and screens

0

5. Dividend

5.1 Amount

ADMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADMA BIOLOGICS INC

NASDAQ:ADMA (9/15/2025, 10:24:00 AM)

15.845

-0.26 (-1.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-05 2025-11-05
Inst Owners90.24%
Inst Owner Change1%
Ins Owners2.35%
Ins Owner Change-1.04%
Market Cap3.78B
Analysts82
Price Target29.64 (87.06%)
Short Float %6.53%
Short Ratio4.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.56%
Min EPS beat(2)-31.17%
Max EPS beat(2)-1.96%
EPS beat(4)1
Avg EPS beat(4)-7.13%
Min EPS beat(4)-31.17%
Max EPS beat(4)13.12%
EPS beat(8)4
Avg EPS beat(8)-13.7%
EPS beat(12)6
Avg EPS beat(12)-7.65%
EPS beat(16)9
Avg EPS beat(16)-4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-2.51%
Revenue beat(4)2
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)10.99%
Revenue beat(8)6
Avg Revenue beat(8)4.93%
Revenue beat(12)10
Avg Revenue beat(12)6.13%
Revenue beat(16)14
Avg Revenue beat(16)6.66%
PT rev (1m)0%
PT rev (3m)-1.46%
EPS NQ rev (1m)-8%
EPS NQ rev (3m)-14.82%
EPS NY rev (1m)-5.63%
EPS NY rev (3m)-13.26%
Revenue NQ rev (1m)0.68%
Revenue NQ rev (3m)-0.98%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.35%
Valuation
Industry RankSector Rank
PE 29.34
Fwd PE 17.16
P/S 7.97
P/FCF 57.63
P/OCF 49.29
P/B 9.49
P/tB 9.59
EV/EBITDA 23.4
EPS(TTM)0.54
EY3.41%
EPS(NY)0.92
Fwd EY5.83%
FCF(TTM)0.27
FCFY1.74%
OCF(TTM)0.32
OCFY2.03%
SpS1.99
BVpS1.67
TBVpS1.65
PEG (NY)1.75
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 37.42%
ROE 52.45%
ROCE 32.19%
ROIC 25.43%
ROICexc 31.27%
ROICexgc 31.6%
OM 32.82%
PM (TTM) 44.06%
GM 53%
FCFM 13.84%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 1.12
Debt/EBITDA 0.45
Cap/Depr 140.25%
Cap/Sales 2.34%
Interest Coverage 13.21
Cash Conversion 46.9%
Profit Quality 31.4%
Current Ratio 5.33
Quick Ratio 2.78
Altman-Z 16.26
F-Score5
WACC9.67%
ROIC/WACC2.63
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y16.79%
EPS Next 2Y35.87%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue 1Y (TTM)43.58%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%13.8%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.46%
Revenue Next 5Y22.46%
EBIT growth 1Y85.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.39%
EBIT Next 3Y41.12%
EBIT Next 5Y36.1%
FCF growth 1Y227.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y285.06%
OCF growth 3YN/A
OCF growth 5YN/A